MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bdi.13288

Медицинская библиотека · Bipolar disorders · 2023

Proof-of-concept randomized controlled trial of single-session nitrous oxide treatment for refractory bipolar depression: Focus on cerebrovascular target engagement.

Kim William S H, Dimick Mikaela K, Omrin Danielle, Mitchell Rachel H B, Riegert Daniel, Levitt Anthony, Schaffer Ayal, Belo Susan, Iazzetta John, Detzler Garfield, Choi Mabel, Choi Stephen, Herrmann Nathan, McIntyre Roger S, MacIntosh Bradley J, Orser Beverley A, Goldstein Benjamin I

Рандомизированное исследованиеСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

There remain few efficacious treatments for bipolar depression, which dominates the course of bipolar disorder (BD). Despite multiple studies reporting associations between depression and cerebral blood flow (CBF), little is known regarding CBF as a treatment target, or predictor and/or indicator of treatment response, in BD. Nitrous oxide, an anesthetic gas with vasoactive and putative antidepressant properties, has a long history as a neuroimaging probe. We undertook an experimental medicine paradigm, coupling in-scanner single-session nitrous oxide treatment of bipolar depression with repeated measures of CBF.

METHODS

In this double-blind randomized controlled trial, 25 adults with BD I/II and current treatment-refractory depression received either: (1) nitrous oxide (20 min at 25% concentration) plus intravenous saline (n = 12), or (2) medical air plus intravenous midazolam (2 mg total; n = 13). Study outcomes included changes in depression severity (Montgomery-Asberg Depression Rating Scale scores, primary) and changes in CBF (via arterial spin labeling magnetic resonance imaging).

RESULTS

There were no significant between-group differences in 24-h post-treatment MADRS change or treatment response. However, the nitrous oxide group had significantly greater same-day reductions in depression severity. Lower baseline regional CBF predicted greater 24-h post-treatment MADRS reductions with nitrous oxide but not midazolam. In region-of-interest and voxel-wise analyses, there was a pattern of regional CBF reductions following treatment with midazolam versus nitrous oxide.

CONCLUSIONS

Present findings, while tentative and based on secondary endpoints, suggest differential associations of nitrous oxide versus midazolam with bipolar depression severity and cerebral hemodynamics. Larger studies integrating neuroimaging targets and repeated nitrous oxide treatment sessions are warranted.

Для цитирования: Kim William S H, Dimick Mikaela K, Omrin Danielle, Mitchell Rachel H B, Riegert Daniel, Levitt Anthony, Schaffer Ayal, Belo Susan, Iazzetta John, Detzler Garfield, Choi Mabel, Choi Stephen, Herrmann Nathan, McIntyre Roger S, MacIntosh Bradley J, Orser Beverley A, Goldstein Benjamin I. Proof-of-concept randomized controlled trial of single-session nitrous oxide treatment for refractory bipolar depression: Focus on cerebrovascular target engagement.. Bipolar disorders. 2023. DOI: 10.1111/bdi.13288.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.